We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche's Actemra Gets FDA Nod for Subcutaneous Formulation
Read MoreHide Full Article
Roche Holding AG’s (RHHBY - Free Report) subsidiary Genentech announced that the FDA has approvedan alternative delivery option for itsrheumatoid arthritis drug Actemra. Asubcutaneous (SC) formulation of Actemra (tocilizumab) for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) for patients two years or older has been approved by the FDA.
Shares of the company have lost 11.1% year to date compared with the industry’s decline of 3%.
We note that Actemra is already approved for PJIA in an intravenous formulation. It is also approved for several other arthritis indications in adults as well as children.
The approval is supported by data from the JIGSAW-117 study to determine the appropriate dosing regimen of Actemra SC based on body weight in children with PJIA. The study enrolled 52 patients aged one to 17 years with PJIA and previous inadequate response or intolerance to methotrexate who were either Actemra naive or were receiving Actemra IV with adequate disease control. The safety observed for Actemra administered subcutaneously was consistent with the known safety profile of Actemra IV.
Sales of Actemra was CHF499 million, an increase of 13% year over year in the first quarter of 2018. A label expansion of the drug will boost Actemra sales.
Ligand’s earnings per share estimates have moved up from $3.91 to $4.09 for 2018 over the past 60 days. The company delivered a positive earnings surprise in all of the trailing four quarters, with an average beat of 31.79%. The company’s shares have rallied 32.4% year to date.
Illumina’s earnings per share estimates have moved up from $4.60 to $4.84 for 2018 and from $5.34 to $5.57 for 2019 over the plast 30 days. The company delivered a positive earnings surprise in all the trailing four quarters, with an average beat of 23.17%. The stock has rallied 68.2% so far this year. The stock has rallied 23.3% so far this year.
Enanta’searnings per share estimates have moved up from 86 cents to $2.97 for 2018 over the past 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 74.2%. The stock has rallied 68.2% so far this year.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Roche's Actemra Gets FDA Nod for Subcutaneous Formulation
Roche Holding AG’s (RHHBY - Free Report) subsidiary Genentech announced that the FDA has approvedan alternative delivery option for itsrheumatoid arthritis drug Actemra. Asubcutaneous (SC) formulation of Actemra (tocilizumab) for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) for patients two years or older has been approved by the FDA.
Shares of the company have lost 11.1% year to date compared with the industry’s decline of 3%.
We note that Actemra is already approved for PJIA in an intravenous formulation. It is also approved for several other arthritis indications in adults as well as children.
The approval is supported by data from the JIGSAW-117 study to determine the appropriate dosing regimen of Actemra SC based on body weight in children with PJIA. The study enrolled 52 patients aged one to 17 years with PJIA and previous inadequate response or intolerance to methotrexate who were either Actemra naive or were receiving Actemra IV with adequate disease control. The safety observed for Actemra administered subcutaneously was consistent with the known safety profile of Actemra IV.
Sales of Actemra was CHF499 million, an increase of 13% year over year in the first quarter of 2018. A label expansion of the drug will boost Actemra sales.
Zacks Rank & Stocks to Consider
Roche currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the same space worth considering are Ligand Pharmaceuticals (LGND - Free Report) , Illumina (ILMN - Free Report) and Enanta Pharmaceuticals (ENTA - Free Report) . While Ligand and Illumina sport a Zacks Rank #1 (Strong Buy), Enanta carries a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings per share estimates have moved up from $3.91 to $4.09 for 2018 over the past 60 days. The company delivered a positive earnings surprise in all of the trailing four quarters, with an average beat of 31.79%. The company’s shares have rallied 32.4% year to date.
Illumina’s earnings per share estimates have moved up from $4.60 to $4.84 for 2018 and from $5.34 to $5.57 for 2019 over the plast 30 days. The company delivered a positive earnings surprise in all the trailing four quarters, with an average beat of 23.17%. The stock has rallied 68.2% so far this year. The stock has rallied 23.3% so far this year.
Enanta’searnings per share estimates have moved up from 86 cents to $2.97 for 2018 over the past 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 74.2%. The stock has rallied 68.2% so far this year.
Roche Holding AG Price
Roche Holding AG Price | Roche Holding AG Quote
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>